Panobinostat and Multiple Myeloma in 2018

FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize t...

Descripción completa

Detalles Bibliográficos
Autores principales: Yee, Andrew J., Raje, Noopur S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2018
Materias:
Commentaries
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947458/
https://www.ncbi.nlm.nih.gov/pubmed/29445026
http://dx.doi.org/10.1634/theoncologist.2017-0644
Descripción
Sumario:FDA and EMA approval of panobinostat offers an additional therapeutic option for multiple myeloma; however, adoption of panobinostat has been limited by its adverse event profile. Trials are ongoing to optimize the dosing of panobinostat and to identify its best partners, in order to fully realize the potential of this drug class.

Ejemplares similares